SCHEMBL1469083

SCHEMBL1469083

COC(=O)C1(OC)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775123 0.90 NPSR1 (0.50)
SCHEMBL25228494 0.90 NPSR1 (0.45)
SCHEMBL15106750 0.89 NPSR1 (0.36)
SCHEMBL14964737 0.84 KDM4E (0.39)
SCHEMBL25478116 0.83 NPSR1 (0.33)
SCHEMBL18806635 0.83 KMT2A (0.36)
SCHEMBL15967442 0.82 NPSR1 (0.35)
Hydrochloric Acid SCHEMBL14964736 0.82 KDM4E (0.38)
SCHEMBL18789280 0.82 NPSR1 (0.35)
SCHEMBL18849596 0.82 NPSR1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-12466821-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2025-11-11 US disclosed
EP-4634159-A1 SULFOXIMINES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-10-22 EP disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed
US-20250145629-A1 ION CHANNEL MODULATORS PRAXIS PRECISION MEDICINES, INC. 2025-05-08 US disclosed
US-12145939-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators PRAXIS PRECISION MEDICINES, INC. (US) 2024-11-19 US disclosed
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 GRUENENTHAL GMBH (DE) 2024-08-01 US disclosed
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 WO disclosed
EP-1863763-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-12-12 EP disclosed
EP-1816122-A2 3,4,5-substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2007-08-08 EP disclosed
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds SPEEDEL EXPERIMENTA AG (CH) 2007-07-19 US disclosed
WO-2007053346-A1 PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-05-10 WO disclosed
WO-2006103275-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-10-05 WO disclosed
EP-1660477-A1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS Schering Corporation (US) 2006-05-31 EP disclosed
WO-2005014577-A9 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORP (US) 2006-03-23 WO disclosed
US-20050059672-A1 Novel farnesyl protein transferase inhibitors as antitumor agents SCHERING CORPORATION 2005-03-17 US disclosed
WO-2005014577-A1 NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS SCHERING CORPORATION (US) 2005-02-17 WO disclosed
US-4166735-A Cycloalkanecarboxanilide derivative herbicides SHELL OIL COMPANY (US) 1979-09-04 US disclosed